Boston Scientific Corp. (NYSE:BSX) shelled out nearly $10 million in cash and just under $40 million in stock awards and options to its two chief executives in 2009, according to regulatory filings.

The payments by the Natick, Mass.-based medical devices giant, made to former CEO James Tobin and his successor, Raymond Elliot, were inflated due to executive compensation triggers in Tobin’s transition and retirement agreement.

Tobin, who officially retired his post in July 2009 after a decade with the company, pulled in about $6.2 million in salary and bonuses in 2009, on top of stock options valued at $7.4 million.

Tobin’s base salary was $909,588, but he received a career service award of $1.5 million, a performance award of roughly $1 million and a severance payment of $2.2 million. He also received about $600,000 in reimbursement for legal costs associated with his retirement, pay-outs for vacation time and other deferred compensation.

Elliott, who took the reins from Tobin last summer, also made out nicely. He pulled in just under $600,000 in salary, $1.5 million in bonuses and $1.2 million in “all other compensation,” including a $1 million relocation payment for resettling in the Boston area. Elliot was also given stock options and option awards valued at $30 million, according to a proxy statementfiled with the Securities & Exchange Commission.

Elliot wasted no time in putting his stamp on the company after taking over, initiating a major restructuring, paying down a significant amount of debt and settling long-standing patent infringement lawsuits with competitors like Johnson & Johnson (NYSE:JNJ). Those moves have been painful for shareholders, who’ve seen the share price dip by nearly 30 percent since the beginning of July. Boston Scientific shares were trading at $7.23 in mid-afternoon trading March 30.